MEDICAL SCIENCERisk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease☆
References (23)
- et al.
Current concepts in unstable myocardial ischaemia
Am Heart J
(1988) - et al.
Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome
Lancet
(1981) - et al.
Persantin-Aspirin Reinfarction Study. Part II. Secondary prevention with persantin and aspirin
JACC
(1986) - et al.
Predictive importance of clinical findings and a predischarge exercise test in suspected unstable coronary artery disease
Am J Cardiol
(1987) - et al.
Platelet inhibitor drugs role in coronary artery disease
Prog Cardiovasc Dis
(1987) - et al.
Superior antiplatelet action of alternate day pulsed dosing versus split dose administration of aspirin
Am J Cardiol
(1989) - et al.
Heparin induced increase of t-PA antigen plasma levels in patients with unstable angina: no evidence for clinical benefit of heparinization during the initial phase of treatment
Thrombos Res
(1989) - et al.
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy
Am J Cardiol
(1984) - et al.
Insights into the pathogenesis of acute ischaemic syndromes
Circulation
(1988) - et al.
Aspirin, heparin or both to treat acute unstable angina
N Engl J Med
(1988)
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
N Engl J Med
(1983)
Cited by (930)
The Changing Epidemiology of the Cardiac Intensive Care Unit
2024, Critical Care ClinicsTen things to know about ten cardiovascular disease risk factors – 2022
2022, American Journal of Preventive CardiologyA manual and portable centrifuge combined with a paper-based immunoassay for myocardial infarction diagnosis
2021, Chemical Engineering JournalTen things to know about ten cardiovascular disease risk factors
2021, American Journal of Preventive CardiologyMeta-Analysis of the Efficacy and Safety of P2Y<inf>12</inf> Inhibitor Monotherapy After Short Course of Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
2020, Cardiovascular Revascularization MedicineTen things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)
2020, American Journal of Preventive Cardiology
- ☆
Correspondence to Dr L. Wallentin, MD, Division of Cardiology, University Hospital, S-581 85 Linkoping, Sweden
Copyright © 1990 Published by Elsevier Ltd.